According to Benzinga Pro, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 6.13 ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...

Last week, President Trump sent letters to 17 major pharmaceutical companies advising them to work with his administration to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

The Phase III magnitude study for ATTR cardiomyopathy is expanding to 1,200 patients, with a targeted cumulative enrollment of at least 650 patients by year-end 2025 and full enrollment by early 2027.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...